PLATELET-RICH PLASMA (PRP) IS AN EMERGING BIOLOGICAL TREATMENT OPTION FOR MUSCULOSKELETAL INJURIES. ALTHOUGH THERE IS A GROWING BODY OF EVIDENCE FOR THIS INTERVENTION, A CONSENSUS REMAINS DISTANT REGARDING PREPARATION PARAMETERS, NUMBER OF INJECTIONS, POSTPROCEDURAL CARE, AND VALUE WITHIN THE REALM OF ALTERNATIVE TREATMENT OPTIONS. THIS POINT-COUNTERPOINT COLUMN PROVIDES A BALANCED PERSPECTIVE ON SOME OF THE MORE COMMON POINTS OF CONTENTION SURROUNDING THE USE OF PRP.
1Department of Physical Therapy, Nova Southeastern University, Fort Lauderdale, Florida; and
2Krannert School of Physical Therapy College of Health Sciences, University of Indianapolis, Indianapolis, Indiana
Address correspondence to Dr. Morey J. Kolber, firstname.lastname@example.org.
Conflicts of interest and source of funding: The authors report no conflicts of interest and no source of funding.
The purpose of the Point/Counterpoint Column is to provide a respectful and balanced discussion in relation to controversial or current topics in the fields of strength and conditioning, nutrition, and human performance.
COLUMN EDITOR: Andrew J. Galpin, PhD, CSCS*D, NSCA-CPT*D
Morey J. Kolberis a professor at Nova Southeastern University in the Department of Physical Therapy.
Paul A. Salamhis an assistant professor in the Krannert School of Physical Therapy College of Health Sciences, University of Indianapolis.